Loading...
XKRX214390
Market cap114mUSD
Jan 09, Last price  
6,910.00KRW
1D
0.00%
Jan 2017
-50.18%
IPO
-78.28%
Name

Kyongbo Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:214390 chart
P/E
55.54
P/S
0.76
EPS
124.42
Div Yield, %
0.72%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
1.45%
Revenues
216.36b
+10.24%
169,781,246,180178,032,632,080186,726,169,860191,661,374,450201,343,595,540191,706,189,110215,285,095,140170,659,645,040196,264,902,080216,357,481,790
Net income
2.97b
+387.14%
8,635,953,72026,109,623,15012,705,929,80017,963,309,61013,116,049,3905,285,239,3909,404,446,290-7,495,178,990610,590,0902,974,400,460
CFO
4.84b
-52.16%
16,041,866,8704,240,141,97025,328,802,77025,805,145,560-1,138,159,26023,668,110,96020,795,227,48017,967,902,72010,126,730,8404,844,320,330
Dividend
Dec 27, 202350 KRW/sh

Profile

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients in South Korea. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also exports its products to 30 countries worldwide. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan, South Korea.
IPO date
Jun 29, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
216,357,482
10.24%
196,264,902
15.00%
Cost of revenue
192,719,295
178,960,338
Unusual Expense (Income)
NOPBT
23,638,187
17,304,564
NOPBT Margin
10.93%
8.82%
Operating Taxes
(802,476)
(1,225,426)
Tax Rate
NOPAT
24,440,663
18,529,991
Net income
2,974,400
387.14%
610,590
-108.15%
Dividends
(1,195,343)
(1,195,343)
Dividend yield
0.60%
0.50%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
74,262,254
64,270,589
Long-term debt
4,380,675
628,754
Deferred revenue
(2,349,180)
Other long-term liabilities
1,988,291
1,030,299
Net debt
59,619,585
45,736,094
Cash flow
Cash from operating activities
4,844,320
10,126,731
CAPEX
(10,877,137)
(13,183,820)
Cash from investing activities
(14,267,871)
(14,877,198)
Cash from financing activities
7,159,152
6,588,722
FCF
13,420,225
16,652,476
Balance
Cash
5,347,057
7,218,480
Long term investments
13,676,287
11,944,769
Excess cash
8,205,469
9,350,003
Stockholders' equity
107,986,000
108,640,458
Invested Capital
214,100,540
197,381,059
ROIC
11.88%
9.57%
ROCE
10.63%
8.28%
EV
Common stock shares outstanding
23,907
23,907
Price
8,390.00
-16.10%
10,000.00
-6.98%
Market cap
200,578,555
-16.10%
239,068,600
-6.98%
EV
260,198,141
284,804,694
EBITDA
35,337,007
29,240,300
EV/EBITDA
7.36
9.74
Interest
3,400,954
1,671,078
Interest/NOPBT
14.39%
9.66%